Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Stocktwits on MSN1h
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong
($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...
Yahoo22h
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
FierceBiotech1d
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
STAT1d
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
GlobalData on MSN11h
Arrowhead and Sarepta link for rare genetic disease treatments
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.C2GW7kSb.js ...
Sarepta Therapeutics’ Strategic Alliance with Arrowhead Pharmaceuticals Secures Future Growth
William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...